Read More

Why Regeneron Stock Is Trading Lower Today

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler.

REGN